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Purpose: Liﬁtegrast is a lymphocyte functioneassociated antigen-1 antagonist developed to reduce
inﬂammation in dry eye disease (DED). We report the results of OPUS-3 (NCT02284516), a phase III study
evaluating the efﬁcacy and safety of liﬁtegrast versus placebo in participants with DED.
Design: Twelve-week, phase III, randomized, double-masked, multicenter, placebo-controlled study.
Participants: Adults aged 18 years with Schirmer tear test (without anesthesia) 1 and 10 mm, corneal
ﬂuorescein staining score 2.0 (0e4 scale), eye dryness score (EDS) 40 (0e100 visual analogue scale [VAS]),
and history of artiﬁcial tear use within 30 days of study entry.
Methods: After a 14-day placebo run-in, participants were randomized 1:1 to liﬁtegrast ophthalmic solution
5.0% or placebo twice daily for 84 days.
Main Outcome Measures: The primary efﬁcacy end point was change from baseline to day 84 in EDS. Key
secondary efﬁcacy end points were change from baseline to days 42 and 14 in EDS. Other secondary efﬁcacy
end points included additional VAS items (burning/stinging, itching, foreign body sensation, eye discomfort,
photophobia, pain), ocular discomfort score (ODS), and safety/tolerability of liﬁtegrast versus placebo.
Results: In the study, 711 participants were randomized: placebo, 356; liﬁtegrast, 355 (intention-to-treat [ITT]
population). At day 84, liﬁtegrast-treated participants experienced signiﬁcantly greater improvement from base-
line in EDS versus those receiving placebo (treatment effect [TE], 7.16; 95% conﬁdence interval [CI], 3.04e11.28;
P ¼ 0.0007). Mean changes from baseline in EDS also signiﬁcantly favored liﬁtegrast on days 42 (TE, 9.32;
95% CI, 5.44e13.20; P < 0.0001) and 14 (TE, 7.85; 95% CI, 4.33e11.37; P < 0.0001). No statistically signiﬁcant
differences were observed in ODS between treatment groups at days 84, 42, or 14. A greater improvement was
observed in liﬁtegrast-treated participants at day 42 in itching (nominal P ¼ 0.0318), foreign body sensation
(nominal P ¼ 0.0418), and eye discomfort (P ¼ 0.0048) versus participants receiving placebo. Most treatment-
emergent adverse events were mild to moderate in severity; no serious ocular adverse events were reported.
Conclusions: Liﬁtegrast signiﬁcantly improved symptoms of eye dryness, as measured by EDS, versus
placebo in participants with DED. Improvement in EDS was observed as early as day 14. Liﬁtegrast appeared well
tolerated. Ophthalmology 2017;124:53-60 ª 2016 by the American Academy of Ophthalmology. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Dry eye disease (DED) is a common ocular condition that
can have a signiﬁcant impact on daily functioning and
quality of life.1 Symptoms vary between patients and can
include eye dryness, irritation, burning, foreign body
sensation, and ﬂuctuating visual disturbances. Although
the cause of DED has not been fully elucidated, the
available evidence suggests that inﬂammation of the
ocular surface and lacrimal gland may have a key role in
the pathogenesis of the disease and the downstream
sequelae.2
Although some options are available to alleviate the signs
or the symptoms of DED, such as artiﬁcial tear substitutes,ª 2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.topical cyclosporine, topical or systemic corticosteroids, and
punctal plugs,3 there remains a need for treatments that
address both the symptoms and the resulting ocular
surface damage. Liﬁtegrast ophthalmic solution 5.0%
recently has been approved by the U.S. Food and Drug
Administration for the treatment of signs and symptoms of
DED in adult patients. Liﬁtegrast is a lymphocyte
functioneassociated antigen-1 antagonist that blocks the
binding of intercellular adhesion molecule-1 to lymphocyte
functioneassociated antigen-1 on the T-cell surface, thereby
inhibiting the T-cell recruitment, activation, and proin-
ﬂammatory cytokine release associated with DED.453http://dx.doi.org/10.1016/j.ophtha.2016.09.025
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Ophthalmology Volume 124, Number 1, January 2017Evidence supporting the efﬁcacy and safety of treatment
with liﬁtegrast ophthalmic solution 5.0% in DED is derived
from the results of 4 previous randomized clinical trials.
These included a phase II study,5 the phase III efﬁcacy and
safety trials OPUS-16 and OPUS-2,7 and the 1-year safety
trial SONATA.8 In all trials, liﬁtegrast appeared to be well
tolerated. Review of results across the 3 trials that
assessed efﬁcacy reveals that liﬁtegrast improved DED
signs (inferior corneal staining score [ICSS]) among
participants with mild to moderate baseline
symptomatology in the phase II study and OPUS-1, and
DED symptoms (as measured by eye dryness score [EDS],
visual analogue scale [VAS]) in participants with moderate
to severe baseline symptomatology (EDS 40 and recent
artiﬁcial tear use) in a post hoc analysis of OPUS-1, and as a
co-primary end point in the OPUS-2 trial.5e7
The objective of the OPUS-3 study was to evaluate the
efﬁcacy and safety of liﬁtegrast ophthalmic solution 5.0%
compared with placebo in participants with DED of mod-
erate to severe symptomatology to conﬁrm the ﬁndings of
symptom improvement demonstrated in OPUS-2.Methods
This was a phase III, randomized, double-masked, multicenter,
placebo-controlled study conducted in 41 study centers in the
United States. The study was compliant with the Health Insurance
Portability and Accountability Act and adhered to the tenets of the
Declaration of Helsinki. Ethics committee approval was obtained
before study initiation. All participants provided written informed
consent. The trial was registered at ClinicalTrials.gov (identiﬁer
NCT02284516).
Participants
All participants were recruited from eye clinics in the United
States. Patients were eligible if they were aged 18 years with a
self-reported history of DED and all of the following: best-
corrected visual acuity of 0.7 logarithm of the minimum angle
of resolution in both eyes at visit 1, corneal ﬂuorescein staining
score 2 (0- to 4-point scale) in 1 region (superior, inferior, or
central) in at least 1 eye, VAS score 40 for EDS in both eyes,
conjunctival redness score 1 in at least 1 eye, use of artiﬁcial tears
within 30 days before the screening visit, and a positive response in
at least 1 eye speciﬁed as meeting the following criteria in the same
eye at visits 1 and 2: ICSS 0.5 and Schirmer Tear Test (without
anesthesia) 1 mm and 10 mm. Individuals with secondary
Sjögren’s syndrome were eligible to participate if they were not
immunodeﬁcient/immunosuppressed, were not taking systemic
steroids, and met all other inclusion and exclusion criteria.
The following individuals were excluded from the study:
women who were pregnant, men or women with hypersensitivity to
the investigational product, previous randomization in a liﬁtegrast
trial, use of any topical medication or antibiotic for the treatment of
blepharitis or meibomian gland disease during the study, ocular
herpes or any other ocular infection within 30 days of the screening
visit, any blood donation or signiﬁcant blood loss within 56 days of
the screening visit, ocular conditions or chronic illness that could
affect study parameters (e.g., glaucoma), a disorder causing
immunodeﬁciency, history of LASIK or similar surgery within the
previous 12 months, history of yttrium aluminum garnet-laser
posterior capsulotomy in the past 6 months, known history of
alcohol/drug abuse that might interfere with study participation,54those unwilling to avoid wearing contact lenses during the study
period, and those with DED secondary to scarring or destruction of
conjunctival goblet cells. Prohibited medications during the study
were topical cyclosporine or any other ophthalmic medication,
including artiﬁcial tears, antihistamines, corticosteroids, or mast
cell stabilizers.
Study Protocol
The investigational product was supplied as a sterile,
preservative-free, clear aqueous solution containing 5.0% liﬁte-
grast with approximately 0.25 ml in each dose vial. During the
screening period (days 14 to 0), all participants received twice-
daily open-label placebo administered as a single eye drop in both
eyes to assess compliance with twice-daily medication (Fig 1).
During the treatment period (days 0e84) (Fig 1), participants
received twice-daily doses (upon awakening and just before
bedtime) of liﬁtegrast ophthalmic solution 5.0% or matching
placebo administered to the ocular surface as a single eye drop in
each eye. Compliance with treatment was assessed by reviewing
the returned investigational product from participants. Participants
who were considered noncompliant (taking <80% or >120% of
the expected doses between visits) after 2 consecutive visits were
withdrawn from the study.
Participants were randomly assigned to treatment on the basis
of a ratio of 1:1 (liﬁtegrast:placebo) within the randomization strata
using permuted blocks. Randomization was centralized across
study centers and stratiﬁed by baseline ICSS score (1.5 or >1.5)
and EDS (<60 or 60) to ensure balance among the treatment
groups. An interactive response technology was used to facilitate
participant randomization accounting for the stratiﬁcation factors.
All study personnel were masked with regard to treatment as-
signments. Investigational product packaging was standardized
such that liﬁtegrast and placebo were visually indistinguishable.
The treatment assignment was not broken during the study.
Outcome Measures
The VAS and ocular discomfort score (ODS) were assessed at
each study visit. The VAS is a 7-item, participant-reported
symptom index (0e100 scale; 0 ¼ no discomfort, 100 ¼
maximal discomfort), with items of eye dryness, burning/stinging,
itching, foreign body sensation, eye discomfort, photophobia, and
pain. Participants were asked to subjectively rate each ocular
symptom (both eyes) by placing a vertical mark on the horizontal
line of 0 to 100 to indicate the level of discomfort. The ODS was
graded by the participant using a 5-point integer scale (0 ¼ no
discomfort, 4 ¼ severe discomfort) for each eye at all study visits.
The eye with the worst (highest) ICSS at day 0 was designated as
the study eye.
The primary efﬁcacy end point was change from baseline to
day 84 in the EDS of the VAS. Key secondary efﬁcacy end points
were change from baseline to days 42 and 14 in EDS. The sec-
ondary efﬁcacy end points were change from baseline to each visit
in the 6 additional items of the 7-item VAS (burning/stinging,
itching, foreign body sensation, eye discomfort, photophobia,
pain), change from baseline to each visit in the designated study
eye in ODS, and safety and tolerability of liﬁtegrast compared with
placebo. The VAS scores were reported as a single score for
both eyes.
All adverse events (AEs) recorded after starting treatment with
the investigational product were considered treatment-emergent
AEs (TEAEs). The investigator assessed AEs for severity (mild,
moderate, severe) and seriousness. Investigator verbatim terms
were coded using the Medical Dictionary for Regulatory Activities
(version 14.1) to Medical Dictionary for Regulatory Activities
Figure 1. Study design. BID ¼ twice daily; ITT ¼ intention-to-treat.
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ocular burning on instillation of study drug were coded to the
Preferred Term of instillation site irritation. Blurred/blurry vision,
ocular discomfort, or drop discomfort on instillation (including
drop comfort score [DCS] >3 at 15 minutes postinstillation) were
coded to instillation site reaction. Verbatim terms for dysgeusia
included but were not limited to bitter or metallic taste in the mouth
on instillation.
Other safety assessments (measured at screening [visit 1],
baseline [visit 2], and at subsequent visits for each eye)
were conjunctival redness score (0 ¼ none, 4 ¼ severe; 0.5-point
increments), corneal ﬂuorescein staining score (0 ¼ no staining,
4 ¼ severe; 0.5-point increments; superior, central, and inferior
corneal zones), conjunctival staining score with lissamine green
(0 ¼ no staining, 4 ¼ severe; 0.5-point increments), Schirmer Tear
Test, best-corrected visual acuity, slit-lamp biomicroscopy, and
dilated fundoscopy. In addition, assessments of DCS (scale 0e10;
0 ¼ very comfortable, 10 ¼ very uncomfortable) were obtained at
baseline and subsequent visits for each eye at instillation and at 1,
2, and 3 minutes after instillation. If the DCS was not 3 at
3 minutes the assessment was repeated at 5, 10, and 15 minutes
until the DCS was 3. If the DCS was >3 at 15 minutes, it was
recorded as an AE (coded under instillation site reaction).
Statistical Methods
The overall type I error (2-sided 5% level) was maintained by
sequential testing of hypotheses for the primary and 2 key
secondary efﬁcacy end points. A sample size of 350 participants
per treatment group was estimated to ensure >90% power to detect
a difference of 10.0 units (standard deviation [SD], 36.0) in the
primary end point of mean change from baseline to day 84 in EDS
between liﬁtegrast and placebo at a 2-sided 5.0% type I error, and
>85% power to detect a difference of 8.0 units (SD, 34.0) in mean
change from baseline to day 42 between the treatment groups, and
>80% power to detect a difference of 6.5 units (SD, 30.0) in mean
change from baseline to day 14 between treatment groups. The
target treatment differences (and SDs) for the primary and key
secondary efﬁcacy end points were based on the results of the
OPUS-2 study.7
All hypothesis tests were performed at the 2-sided 5% alpha
level of signiﬁcance, and associated 95% conﬁdence intervals (CIs)
were computed. Multiplicity adjustments were done for the pri-
mary and key secondary efﬁcacy end points by sequential testing.
The primary and key secondary end points were compared among
the treatment groups using a stratiﬁed 2-sample t test (i.e., analysis
of variance). The analysis of variance model included treatment,
randomization strata, and the interaction between treatment and
strata. This approach also was used to analyze the change from
baseline to day 84 in ICSS.The intention-to-treat (ITT) and safety populations included all
randomized participants who received 1 dose of investigational
product. All efﬁcacy analyses were performed on the ITT popu-
lation and presented by randomized treatment group. All safety
analyses were performed on the safety population based on the
treatment received. All efﬁcacy analyses were performed using last
observation carried forward, unless stated otherwise.
Protocol Amendments
The original study protocol was amended twice as follows: (1) On
December 22, 2014, the exclusion criteria language was revised to
specify prior randomization in a liﬁtegrast clinical study; and (2) on
May 14, 2015, the schedule of assessments was updated to ensure the
requirements for dilated fundoscopy were consistent throughout the
protocol. The protocol also was revised to clarify that the in-
vestigators could use their discretion to determine whether DED
progression or slit-lamp biomicroscopy changes that were consid-
ered not clinically signiﬁcant should be considered as AEs.
Results
Participants
The study was conducted between November 2014 and October
2015. Of the 1542 participants screened, 711 participants were
randomized (liﬁtegrast, n ¼ 355; placebo, n ¼ 356) (Fig 2) and 637
completed the trial. Two participants were randomized to the
placebo group but erroneously received liﬁtegrast. These
participants were included in the liﬁtegrast group for the safety
population, but in the placebo group for the randomized and ITT
populations.
Baseline characteristics were similar between treatment groups
(Table 1). Participants’ ages ranged from 18 to 93 years, with a
mean (SD) age of 58.7 (14.47) years. The majority of
participants were female (75.5%) and white (76.5%). All
participants had an ocular medical history of DED (i.e., the
primary diagnosis). Except for the primary diagnosis, the most
common (>10%) occurrences in ocular medical history for all
participants were cataract (33.9%), cataract operation (13.1%),
and keratomileusis (10.1%). In relation to nonocular medical
history, the most common (>10%) occurrences were
hypertension (38.3%), postmenopause (35.3%), hysterectomy
(20.7%), gastroesophageal reﬂux disease (18.6%),
hypothyroidism (13.8%), drug hypersensitivity (12.5%),
depression (12.2%), and hyperlipidemia (10.5%).
The mean (SD) ICSS score at baseline was 2.46 (0.744) in the
placebo group and 2.46 (0.684) in the liﬁtegrast group; mean (SD)
EDS was 69.0 (17.08) and 68.3 (16.88), respectively. The sec-
ondary efﬁcacy end point of ODS at baseline corresponded to mild55
Figure 2. Participant ﬂow. Two participants randomized to the placebo group erroneously received liﬁtegrast and thus were included in the liﬁtegrast group
for the safety population and in the placebo group for the randomized and intention-to-treat (ITT) populations.
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liﬁtegrast, 2.0 [1.14] vs. placebo, 2.0 [1.10]). To balance treatment
assignment across baseline severity, randomization was stratiﬁed
by ICSS (1.5 or >1.5) and EDS (<60 or 60) in the study eye
(Table 2). Most participants (placebo, 54.8%; liﬁtegrast, 54.9%)
had ICSS >1.5 and EDS 60 at randomization.
Overall, 2.4% of participants took an ocular concomitant
medication for ocular health with a start date on or after the ﬁrst
dose of investigational product. Although concomitant artiﬁcial
tear use was not permitted per protocol, the most common ocular
concomitant medication was Tears Plus (Allergan, USA; 0.4%).
Overall, 78.9% of participants took concomitant nonocular medi-
cations. The most common (>10%) were acetylsalicylic acid
(41.6%), Viterra (Pﬁzer, UK; vitamins; 13.4%), cholecalciferol
(13.6%), and lisinopril (11.1%).
On the basis of investigational product vials returned, 97.6% of
placebo-treated and 96.5% of liﬁtegrast-treated participants were
compliant with study treatment. The mean (SD) duration of treat-
ment was similar between treatment groups (placebo, 79.8 [17.37]
days; liﬁtegrast, 79.3 [18.49] days).56Efﬁcacy Findings
At day 84, liﬁtegrast-treated participants experienced signiﬁcant
improvement from baseline in EDS (VAS) versus participants
receiving placebo (treatment effect [TE], 7.16; 95% CI,
3.04e11.28; P ¼ 0.0007), meeting the primary efﬁcacy end point
(Fig 3). Mean changes from baseline in EDS (VAS) also
signiﬁcantly favored liﬁtegrast over placebo on day 42 (TE,
9.32; 95% CI, 5.44e13.20; P < 0.0001) and day 14 (TE, 7.85;
95% CI, 4.33e11.37; P < 0.0001), meeting both key secondary
end points (Fig 3). The numbers of participants in each strata
(ICSS [1.5 or >1.5] and EDS [<60 or 60]) were not high
enough to allow meaningful conclusions regarding treatment
response by strata.
Overall, ODS decreased during the study in both treatment
groups, but there were no statistically signiﬁcant differences in
mean (standard error) change from baseline in ODS of the study
eye between the groups at day 84 (TE, 0.04 [0.095]; P ¼ 0.6655),
day 42 (TE, 0.14 [0.090]; P ¼ 0.1293), or day 14 (TE, 0.01
[0.089]; P ¼ 0.8893).
Table 1. Demographics of Randomized Population
Characteristic
Placebo
n [ 356
Liﬁtegrast
n [ 355
Total
n [ 711
Age (yrs), mean (SD) 58.6 (14.84) 58.8 (14.10) 58.7 (14.47)
>65, no. (%) 137 (38.5) 128 (36.1) 265 (37.3)
>75, no. (%) 44 (12.4) 48 (13.5) 92 (12.9)
Female, no. (%) 269 (75.6) 268 (75.5) 537 (75.5)
Ethnicity, no. (%)
Hispanic or Latino 58 (16.3) 60 (16.9) 118 (16.6)
Not Hispanic or Latino 298 (83.7) 295 (83.1) 593 (83.4)
Race, no. (%)
American Indian or
Alaskan Native
0 2 (0.6) 2 (0.3)
Asian 24 (6.7) 24 (6.8) 48 (6.8)
Black or African American 47 (13.2) 48 (13.5) 95 (13.4)
Native Hawaiian/other
Paciﬁc Islander
1 (0.3) 2 (0.6) 3 (0.4)
White 279 (78.4) 265 (74.6) 544 (76.5)
Other 5 (1.4) 14 (3.9) 19 (2.7)
SD ¼ standard deviation.
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Figure 3. Eye dryness score (EDS) (visual analogue scale [VAS]);
intention-to-treat population with last observation carried forward. EDS
(0- to 100-point VAS; both eyes). Treatment effect, *P ¼ 0.0007 (day 84),
P < 0.0001 (days 42 and 14). SE ¼ standard error.
Holland et al  The OPUS-3 TrialImprovements from baseline were observed in both treatment
groups for all VAS symptoms at days 84, 42, and 14, on the basis
of last observation carried forward. Compared with the placebo
group, a greater mean (standard error) improvement from baseline
was observed in the liﬁtegrast group at day 42 for itching (TE, 4.17
[1.940]; nominal P ¼ 0.0318), foreign body sensation (TE, 4.43
[2.172]; nominal P ¼ 0.0418), and eye discomfort (TE, 5.86
[2.071]; nominal P ¼ 0.0048). The mean changes from baseline to
day 42 were similar between treatment groups for participant-
reported burning/stinging, photophobia, and pain. The mean
changes from baseline at days 14 and 84 were similar between
treatment groups for all VAS symptoms except EDS.
Ad Hoc Analysis
An ad hoc analysis of ICSS in the ITT population demonstrated a
reduction from baseline to day 84 that signiﬁcantly favored liﬁte-
grast over placebo (study eye; TE, 0.17; 95% CI, 0.03e0.30;
nominal P ¼ 0.0144). The 95% CI crossed zero on days 42 and
day 14.
Safety Findings
Overall, a higher percentage of participants in the liﬁtegrast group
(48.2%) had TEAEs than in the placebo group (24.6%) (Table 3).
There also was a higher percentage of treatment-related TEAEs in
the liﬁtegrast group (ocular, 35.3%; nonocular, 14.6%) than in the
placebo group (ocular, 13.3%; nonocular, 0.8%).Table 2. Number of Participants in Randomization Strata
(Randomized Population)
Inferior Corneal
Score at Baseline
Eye Dryness
Score at Baseline
Placebo
n [ 356,
No. (%)
Liﬁtegrast
n [ 355,
No. (%)
1.5 <60 20 (5.6) 19 (5.4)
60 33 (9.3) 32 (9.0)
>1.5 <60 108 (30.3) 109 (30.7)
60 195 (54.8) 195 (54.9)Most ocular and nonocular TEAEs were mild to moderate in
severity, and few participants had severe ocular (0.6%) or non-
ocular (1.0%) TEAEs. Eight serious TEAEs were reported (pla-
cebo, 1.1%; liﬁtegrast, 1.1%), all of which were nonocular and
considered not related to the study drug by the investigator. No
serious ocular TEAEs were reported (Table 3).
The most common ocular TEAEs, occurring in >5% of par-
ticipants in either treatment group, were instillation site irritation
and instillation site reaction, all cases of which were mild to
moderate in severity. The most common nonocular TEAE was
dysgeusia (placebo, n ¼ 1 [0.3%]; liﬁtegrast, n ¼ 46 [12.9%])
(Table 3), which was also mild to moderate in all affected
participants. No other nonocular TEAE was reported by >5
participants. Similar proportions of participants in each treatment
group reported nonocular infections and infestations (liﬁtegrast,
3.4%; placebo, 3.1%), and the observed safety proﬁle
demonstrated no pattern of AEs suggesting systemic toxicities,
localized or systemic infections, or immunosuppressive
complications.
Discontinuations due to TEAEs were infrequent (liﬁtegrast,
5.9%; placebo, 2.5%) (Table 3). The most common TEAEs that
led to treatment discontinuation were instillation site reaction
(placebo, n ¼ 2; liﬁtegrast, n ¼ 5) and instillation site irritation
(placebo, n ¼ 0; liﬁtegrast n ¼ 4). A total of 9 participants were
discontinued from treatment because of a nonocular TEAE
(placebo, n ¼ 3; liﬁtegrast, n ¼ 6). Each nonocular TEAE that
led to treatment discontinuation occurred in only 1 participant,
with the exception of headache that occurred in 2 participants in
the liﬁtegrast group. In both treatment groups, most ocular and
nonocular TEAEs that led to discontinuation were considered
mild to moderate in severity and resolved.Other Ocular Safety Parameters
Although the magnitude of change was small, conjunctival redness
score, corneal ﬂuorescein staining score (including ICSS, ad hoc
analysis reported earlier), conjunctival lissamine green staining,
and Schirmer tear test displayed greater numeric improvement over57
Table 3. Summary of Ocular and Nonocular Treatment-Emergent Adverse Events (Safety Population)
TEAEs, no. (%) Placebo n [ 354 Liﬁtegrast n [ 357 Total n [ 711
Participants with 1 TEAE 87 (24.6) 172 (48.2) 259 (36.4)
Ocular TEAEs 63 (17.8) 141 (39.5) 204 (28.7)
Mild 46 (13.0) 113 (31.7) 159 (22.4)
Moderate 15 (4.2) 26 (7.3) 41 (5.8)
Severe 2 (0.6) 2 (0.6) 4 (0.6)
Nonocular TEAEs 29 (8.2) 84 (23.5) 113 (15.9)
Mild 20 (5.6) 60 (16.8) 80 (11.3)
Moderate 8 (2.3) 18 (5.0) 26 (3.7)
Severe 1 (0.3) 6 (1.7) 7 (1.0)
Participants with TEAEs considered possibly or probably drug related 50 (14.1) 136 (38.1) 186 (26.2)
Ocular TEAEs 47 (13.3) 126 (35.3) 173 (24.3)
Nonocular TEAEs 3 (0.8) 52 (14.6) 55 (7.7)
Participants prematurely withdrawn due to 1 TEAE 9 (2.5) 21 (5.9) 30 (4.2)
Ocular TEAEs 6 (1.7) 17 (4.8) 23 (3.2)
Nonocular TEAEs 3 (0.8) 6 (1.7) 9 (1.3)
Participants with serious TEAEs 4 (1.1) 4 (1.1) 8 (1.1)
Ocular TEAEs 0 0 0
Nonocular TEAEs 4 (1.1) 4 (1.1) 8 (1.1)
Summary of most frequent (>5%) TEAEs
Instillation site irritation* 11 (3.1) 65 (18.2) 76 (10.7)
Instillation site reaction* 19 (5.4) 45 (12.6) 64 (9.0)
Dysgeusia* 1 (0.3) 46 (12.9) 47 (6.6)
TEAE ¼ treatment-emergent adverse event.
*Verbatim terms coding to instillation site irritation, instillation site reaction, and dysgeusia are given in the “Methods” section.
Ophthalmology Volume 124, Number 1, January 2017time in the liﬁtegrast group compared with that in the placebo
group.
In the liﬁtegrast group, numeric improvements in mean DCS of
the study eye at instillation were observed across visits (baseline to
day 84). On days 14, 42, and 84, the majority (64%e66%) of
participants reported DCS <3 at 3 minutes postinstillation. For
participants with DCS >3 at 3 minutes, the mean DCS in the
liﬁtegrast group was similar to or better than that in the placebo
group at 5, 10, and 15 minutes.Discussion
In this study, liﬁtegrast met the primary end point of change
from baseline in patient-reported symptoms, as measured by
EDS in participants with DED with moderate to severe
baseline symptomology and a history of recent artiﬁcial tear
use. The therapeutic beneﬁt of liﬁtegrast on EDS was
observed as early as 2 weeks. Liﬁtegrast was generally
well tolerated, and the safety proﬁle was consistent with
previous liﬁtegrast trials. OPUS-3 replicated, and therefore
conﬁrmed, the results from the OPUS-2 study in a compa-
rable study population. This ﬁnding is noteworthy because,
according to our knowledge, statistically signiﬁcant symp-
tom improvements have not been demonstrated before in 2
separate phase III clinical studies of an investigational drug
therapy for DED.
The data from this study add to the clinical evidence
accumulated from the liﬁtegrast trials to date, which
comprise >2500 patients. In terms of safety, all 5 liﬁtegrast
studies, including the 1-year safety study SONATA,
demonstrated that liﬁtegrast was generally well tolerated,
with no serious ocular TEAEs. Overall, the efﬁcacy results58from OPUS-2 and OPUS-3 suggest that liﬁtegrast improves
symptoms of DED in participants with moderate to severe
baseline symptomology. A post hoc analysis of OPUS-1
also showed symptom improvement among participants
with this severity of baseline symptomatology. Signiﬁcant
improvements versus placebo in EDS were observed at days
84, 42 and 14 in OPUS-3. Of particular note, the observa-
tion that liﬁtegrast signiﬁcantly improved EDS compared
with placebo as early as day 14 is consistent with ﬁndings
from OPUS-2; this early effect of treatment could represent
an appreciable beneﬁt in treating patients with DED. A
numeric improvement from baseline in EDS also was
observed over time in the placebo group, which may have
reduced TE. Such a placebo effect is not uncommon in DED
trials in which patient-reported outcome measures are used,9
but we believe it does not diminish the robustness of the
primary outcome.
In contrast to the effect on symptoms, in prior studies,
improvements in signs with liﬁtegrast have appeared to be
most marked among those with mild to moderate baseline
symptomatology. Because of this discordance between sign
and symptom results in prior studies, the OPUS-3 trial was
designed to speciﬁcally evaluate symptom effects in the
population with moderate to severe DED, and signs were
included as part of the safety assessment. Positive trends
were observed in OPUS-3 for conjunctival redness score,
corneal ﬂuorescein staining score, conjunctival lissamine
green staining, and Schirmer tear test with liﬁtegrast versus
the placebo group.
Among the secondary symptom end points, signiﬁcant
differences between liﬁtegrast and placebo were observed
for change from baseline to day 14 in VAS items of
Holland et al  The OPUS-3 Trialitching, foreign body sensation, and eye discomfort.
However, other secondary end points, including ODS and
VAS items of burning/stinging, photophobia, and pain,
did not show signiﬁcant differences between treatment
groups at any time point measured. This ﬁnding may
relate to how patients describe their DED symptoms. For
example, patients can use different words to describe the
same symptom, reﬂecting individual preferences or in-
ﬂuence during the clinical study (learned word choice).10
The EDS may be the best to capture patient response to
treatment, as suggested by a number of clinical studies
in which dryness was the most frequently reported
symptom.11e14
Overall in this study, liﬁtegrast was well tolerated, with
no serious ocular TEAEs reported; <5% of patients in the
liﬁtegrast group discontinued because of ocular TEAEs.
The most common ocular TEAEs considered related to
liﬁtegrast were instillation site irritation and instillation
site reaction, which were mild to moderate in severity and
occurred in 18.2% and 12.6% of liﬁtegrast-treated par-
ticipants, respectively. These AEs led to discontinuations
in only a small proportion of participants (1.1% and 1.4%
of the liﬁtegrast treatment group, respectively). In addi-
tion to safety, the comfort of an ophthalmic formulation
when instilled in the eye is an important consideration
when evaluating the suitability of a drug therapy for DED,
because it may affect patient adherence to the treatment.
We found that drop tolerability after instillation was
acceptable and improved within 3 minutes of instillation,
reaching values close to those in the placebo group.
Consistent reductions in DCS also occurred across visits
suggesting that drop tolerability of liﬁtegrast improves
with time, which is consistent with observations in prior
trials.6e8
The proportion of liﬁtegrast-treated participants with
nonocular TEAEs appeared high in this study (liﬁtegrast,
23.5% vs. placebo, 8.2%). However, as with ocular TEAEs,
most nonocular TEAEs were mild to moderate in severity.
The most common nonocular TEAE was dysgeusia, which
occurred in 12.9% of participants in the liﬁtegrast group
compared with 0.3% of participants in the placebo group,
and was mild to moderate in severity in all affected partic-
ipants. Dysgeusia is a relatively common AE associated
with instillation of some topical ophthalmic medications and
led to discontinuation of treatment in just 1 participant in the
liﬁtegrast group. Other than dysgeusia, no individual non-
ocular TEAEs occurred in more than 5 participants. The
pattern of AEs in this study did not suggest any evidence of
systemic toxicities, infections, or immunosuppressive
complications.
Study Limitations
Limitations of this study were the relatively short treatment
period of 84 days and a study population that was limited to
patients with at least moderate baseline symptomology.
Other limitations were that patients with a history of LASIK
within 12 months before the study and those wearing con-
tact lenses were excluded from this study, so the efﬁcacy
and safety of liﬁtegrast in these groups were not studied. Inaddition, the study was not powered or designed to assess
corneal staining or other exploratory variables.
In conclusion, building on the cumulative evidence from
prior liﬁtegrast trials, this study demonstrates that liﬁtegrast
signiﬁcantly improved patient-reported symptoms of DED,
as measured by the EDS, from as early as 2 weeks. Liﬁte-
grast was generally well tolerated, and there were no serious
ocular TEAEs. On the basis of the results from OPUS-3 and
previous trials, liﬁtegrast seems to be a promising lympho-
cyte functioneassociated antigen-1 antagonist therapy for
the treatment of signs and symptoms of DED.
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